Brokerages Set Bio-Rad Laboratories, Inc. (NYSE:BIO) Target Price at $395.20

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five analysts that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $395.20.

Several equities research analysts have commented on BIO shares. Royal Bank of Canada restated an "outperform" rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Wells Fargo & Company reduced their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 12th. Finally, StockNews.com lowered Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th.

Bio-Rad Laboratories Trading Down 3.5 %

Shares of Bio-Rad Laboratories stock traded down $8.52 during trading hours on Friday, hitting $236.69. The company's stock had a trading volume of 37,418 shares, compared to its average volume of 316,320. Bio-Rad Laboratories has a 12 month low of $215.38 and a 12 month high of $387.99. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. The company has a market capitalization of $6.63 billion, a PE ratio of -3.64 and a beta of 1.12. The stock has a 50 day moving average of $258.93 and a 200 day moving average of $313.16.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Analysts predict that Bio-Rad Laboratories will post 10.81 earnings per share for the current year.

Hedge Funds Weigh In On Bio-Rad Laboratories

Several large investors have recently modified their holdings of BIO. Venturi Wealth Management LLC boosted its position in shares of Bio-Rad Laboratories by 2,175.0% in the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock valued at $30,000 after acquiring an additional 87 shares during the period. GeoWealth Management LLC grew its position in shares of Bio-Rad Laboratories by 342.9% during the 4th quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock worth $31,000 after purchasing an additional 72 shares in the last quarter. Picton Mahoney Asset Management boosted its stake in shares of Bio-Rad Laboratories by 55.6% in the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock valued at $32,000 after buying an additional 35 shares during the period. Asset Planning Inc acquired a new stake in Bio-Rad Laboratories during the fourth quarter worth approximately $33,000. Finally, Curat Global LLC bought a new position in Bio-Rad Laboratories during the 1st quarter worth $34,000. 65.24% of the stock is owned by institutional investors.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.